益生菌联合美沙拉秦治疗溃疡性结肠炎的临床疗效及对血清炎症指标的影响

Clinical efficacy of probiotics combined with Mesalazine in the treatment of ulcerative colitis and its influence on serum inflammation indexes

目的探讨应用益生菌对溃疡性结肠炎(UC)患者的临床疗效和血清炎症指标的影响。方法选取2016年10月-2018年10月甘肃省人民医院消化内科就诊的轻、中度活动期UC确诊患者为研究对象,将其随机分为治疗组(n=47)和对照组(n=46),治疗组采用益生菌和美沙拉秦联合治疗,对照组采用美沙拉秦单药治疗,两组其余治疗相同。观察、检测并记录两组患者治疗前后的临床表现、结肠镜检查结果、血清炎症相关指标、药物不良反应和医师总体评价。共观察6个月,通过改良Mayo评分系统进行评分,判定临床疗效。比较两组治疗前后临床疗效、血清炎症相关指标及药物不良反应。结果治疗组和对照组的总有效率分别为93.6%和73.9%(P<0.05);两组患者治疗前血清降钙素原(PCT)、C-反应蛋白(CRP)及红细胞沉降率(ESR)的差异无统计学意义(均P>0.05),两组患者治疗后较治疗前血清PCT、CRP及ESR水平下降显著(均P<0.05),同时在治疗后,治疗组与对照组比较血清PCT、CRP及ESR水平下降更显著(均P<0.05);治疗组6例发生不良反应,对照组9例,发生率比较差异无统计学意义(P>0.05)。结论益生菌联合美沙拉秦治疗溃疡性结肠炎可显著提高治疗效果,降低血清炎症指标水平。

Objective To investigate the effect of probiotics on clinical efficacy and serum inflammation indexes in patients with ulcerative colitis(UC). Methods Patients diagnosed with mild or moderate active UC in our hospital from October 2016 to October 2018 were randomly divided into the treatment group(n=47)or control group(n=46).The treatment group was treated with probiotics and Mesalazine;the control group was treated with Mesalazine alone.The clinical manifestations,colonoscopy results,serum inflammation related indexes,adverse drug reactions and overall evaluation were observed,detected and recorded.After 6 months of observation,the clinical efficacy was scored and determined according to the modified Mayo scoring system.And the clinical efficacy,serum inflammation related indexes and adverse drug reactions were compared between the two groups. Results The overall efficiency rate in the treatment group was 93.6%,and that in the control group was 73.9%(P<0.05).There were no statistically significant differences in serum procalcitonin(PCT),C-reactive protein(CRP)and erythrocyte sedimentation rate(ESR)between the two groups before treatment(P>0.05).The levels of serum PCT,CRP and ESR in the two groups decreased significantly after treatment(P<0.05).Compared with the control group,the levels of serum PCT,CRP and ESR in the treatment group decreased more significantly(P<0.05).There were 6 cases of adverse reactions in the treatment group vs 9 cases in the control group.There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05). Conclusion Probiotics combined with Mesalazine can significantly improve the efficacy in the treatment of UC,reduce the levels of serum inflammation indexes,and control the occurrence and development of inflammation.